Abstract: A method for treating or preventing symptoms associated with oral autoimmune diseases comprises treating a patient with an oral topical formulation of azathioprine or a pharmaceutically acceptable salt thereof. The azathioprine formulation may be used in the form of an oral rinse to topically treat areas of oral tissue inflammation and ulceration caused by the onset of oral autoimmune diseases, such as GVHD. The oral topical formulation of azathioprine may also be used in combination with other topical or systemic immunosuppressants or anti-inflammatory drugs.

Abstract: A method for reducing mortality associated with GVHD by treating the patent with an oral BDP regimen that involves co-administration of: 1) a high dose of prednisone (about 1-2 mg/kg/day) for about 10 days, which is then tapered rapidly over the following 7 days to a physiological replacement dose of about 0.0625 mg/kg/day for the remainder of the treatment, and 2) about 4-12 mg oral BDP q.i.d. for about 50 days, where the BDP is administered in both immediate release and enteric coated preparations. Another method is for treating leukemia by performing hematopoietic cell transplantation followed by said regimen.

Abstract: A method of administration of an oral pharmaceutical product to patients suffering from inflammatory disorders of the gastrointestinal tract comprises orally administering to the patient at least two different dosage forms of a therapeutically effective amount of a topically active corticosteroid, such as beclomethasone dipropionate (BDP).